|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
Distance Education to Engage Alaskan Community Health Aides in Cancer Control
|
5R25CA186882-05
|
$135,579
|
|
CUEVA, MELANY
|
ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$109,384
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Identification and targeting of pathways separating healthy stem cell aging from malignant transformation
|
1R01CA230756-01
|
$382,013
|
$382,013
|
WILL, BRITTA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
5R01CA201179-03
|
$655,095
|
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Modeling Neoplastic Progression in Barretts Esophagus
|
5R01CA140657-10
|
$350,771
|
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-15
|
$307,800
|
$307,800
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
A Psychosocial Intervention for the Caregivers of Advanced Lung Cancer Patients
|
5R01CA187143-05
|
$456,456
|
|
BADR, HODA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Crosstalk between the ER Stress Response and Mitochondrial Fatty Acid Oxidation in MYC-driven Breast Cancer
|
1R37CA228304-01
|
$362,569
|
|
CHEN, XI
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ9) Directed and unbiased studies of synaptic injuries as sequelae of radiotherapy: mapping, sex-dependence, and reversal
|
5R01CA219667-02
|
$523,048
|
|
DUMAN, JOSEPH
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQB-1) Telomere maintenance defects and thyroid second cancer in childhood cancer survivors
|
5R01CA194473-04
|
$119,807
|
|
GRAMATGES, MARIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
|
5R01CA181808-05
|
$336,565
|
|
RICHARDS, JOANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Impact of aging on the outcomes of a mouse model of chronic myeloid leukemia
|
4UH3CA213385-03
|
$87,498
|
$87,498
|
CHEN, WENYONG
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
|
5R01CA181045-05
|
$721,537
|
|
DIAMOND, DON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Integration of Palliative Care for Cancer Patients on Phase I Trials
|
5R01CA177562-05
|
$1,384,347
|
|
FERRELL, BETTY
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
City of Hope Lymphoma SPORE
|
2P50CA107399-11A1
|
$2,500,000
|
$900,000
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Geriatric Oncology: Educating nurses to improve quality care
|
5R25CA183723-04
|
$282,678
|
|
HURRIA, ARTI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-04
|
$546,873
|
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
PD-L1 interacts with CD80 and PD-1 to regulate GVHD and GVL activity
|
1R01CA228465-01
|
$404,275
|
|
ZENG, DEFU
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting PML for Leukemia Therapy
|
5R01CA142874-08
|
$457,619
|
$457,619
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.
|
1R44CA228694-01
|
$300,000
|
|
SILBERSTEIN, DAVID
|
BIOMIMETIX JV, LLC
|
|
Discovery and targeting of apoptosis resistance mechanisms in high-risk T-ALL
|
5R01CA193651-04
|
$443,296
|
|
GUTIERREZ, ALEJANDRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Microvasculature in Colon Field Carcinogenesis: Clinical-Biological Implications
|
1R01CA224911-01A1
|
$715,647
|
|
ROY, HEMANT
|
BOSTON MEDICAL CENTER
|
|
Clinical Feasibility of Chemotherapy Monitoring for Sarcoma with Diffuse Optical Spectroscopic Imaging
|
1F31CA221074-01A1
|
$38,082
|
|
PETERSON, HANNAH
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Developing a translational pipeline for NF1-mutant malignancies
|
5U01CA202943-03
|
$235,046
|
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Development of Novel Therapeutic Strategies in Human Leukemias
|
5P01CA066996-20
|
$2,247,411
|
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
SPORE in Myeloid Malignancies
|
5P50CA206963-02
|
$2,300,000
|
$276,000
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Lifestyle, genetics and colonoscopy for colorectal cancer prevention
|
5K07CA190673-06
|
$110,893
|
|
NISHIHARA, REIKO
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus Nuclear Protein B Cell Growth Transformation
|
5R01CA047006-31
|
$532,500
|
|
ZHAO, BO
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A novel small molecule FL7N-1 for treating pediatric cancer retinoblastoma
|
1R43CA221389-01A1
|
$224,919
|
|
LING, XIANG
|
CANGET BIOTEKPHARMA, LLC
|
|
IRF2BP2 modification by Cdk5 modulates interferon-gamma response tumor PD-L1 level
|
5R03CA219725-02
|
$80,000
|
|
PETROSIUTE, AGNE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Unique Deployable Thermosensor Probe for the Minimally Invasive Treatment of Renal Tumors
|
1R43CA224431-01A1
|
$300,000
|
|
VAN BUSKIRK, ROBERT
|
CELL PRESERVATION SERVICES, INC.
|
|
The Development of Novel Mechanistically-based APE/Ref-1 Redox Inhibitors
|
5K08CA179084-05
|
$112,331
|
|
YANG, SUN
|
CHAPMAN UNIVERSITY
|
|
1/2 Cherokee Nation/Stephenson Cancer Center Collaborative on Cancer Disparities
|
5P20CA202923-04
|
$54,305
|
|
KHAN, SOHAIL
|
CHEROKEE NATION
|
|
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion
|
5R01CA189299-04
|
$338,550
|
|
KELLER, CHARLES
|
CHILDREN'S CANCER THERAPY DEVELOP/INST
|
|
KIR-FAVORABLE HAPLOIDENTICAL TRANSPLANTATION IN CHILDREN
|
5R01CA181050-05
|
$291,828
|
|
PULSIPHER, MICHAEL
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Highly Sensitive Chimerism Testing to Detect Early Leukemia Relapse Post-Allo-Transplantation
|
1R41CA232805-01
|
$173,566
|
$86,783
|
KANAAN, SAMI
|
CHIMEROCYTE, INC.
|
|
Programmable Individualized NRT Merged With Digital Behavioral Support
|
5R44CA171786-05
|
$1,000,000
|
|
LEVY, ALAN
|
CHRONO THERAPEUTICS, INC.
|
|
Mechanism of non-oncogene addiction
|
1R01CA211594-01A1
|
$363,713
|
$363,713
|
AZAM, MOHAMMAD
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Leukemia stem cell polarity and differentiation therapy
|
5R01CA204895-02
|
$442,805
|
|
MULLOY, JAMES
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
CryoPen: An Innovative Treatment for Cervical Precancer in Low-Resource Setting
|
5UH3CA189883-06
|
$903,427
|
|
CREMER, MIRIAM
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer
|
1R44CA224472-01A1
|
$298,791
|
|
SUREBAN, SRIPATHI
|
COARE HOLDINGS, INC.
|
|
2/2 Partnership to Study Racial/Ethnic Differences in GI Cancer Biology
|
5P20CA192996-04
|
$154,589
|
|
MCCOMBIE, WILLIAM
|
COLD SPRING HARBOR LABORATORY
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-22
|
$256,101
|
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY
|
|
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
|
5U01CA217858-02
|
$1,314,469
|
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Molecular pathways and targeted therapies in human leukemia
|
5R35CA210065-02
|
$960,000
|
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Role of autophagy in normal and transformed hematopoietic stem cells
|
5R01CA184014-05
|
$332,000
|
$332,000
|
PASSEGUE, EMMANUELLE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Evaluating Notch Signaling as a Therapeutic Target in Ovarian Cancer
|
5F31CA192891-05
|
$49,524
|
|
PRICE, JESSICA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S1
|
$120,000
|
$1,200
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Total relevant funding to Chronic Myeloproliferative Disorders for this search: $19,757,411
|